Controversy over new Alzheimer's drug
A new drug has been approved in the US, sparking a global controversy within Alzheimer's research. This is because 10 out of 11 reviewers rejected the drug for the treatment of Alzheimer's disease. The dementia group of the Cochrane Institute provides a brief overview of the evidence for Aducanumab. For a long time, there was...
